Alnylam Pharmaceuticals
ALNY
#663
Rank
C$42.80 B
Marketcap
$331.86
Share price
-8.67%
Change (1 day)
41.79%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -C$0.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$2.09 Billion. In 2023 the company made an earning of -C$0.44 Billion, an increase over its 2022 earnings that were of -C$1.37 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$0.25 Billion-43.28%
2023 -C$0.44 Billion-67.84%
2022 -C$1.37 Billion36.93%
2021 -C$1 Billion-8.04%
2020 -C$1.09 Billion-15.66%
2019 -C$1.29 Billion12.23%
2018 -C$1.15 Billion62.91%
2017 -C$0.71 Billion17.78%
2016 -C$0.6 Billion43.44%
2015 -C$0.42 Billion60.69%
2014 -C$0.26 Billion98.2%
2013 -C$0.14 Billion
2011 -C$77.23 Million27.48%
2010 -C$60.58 Million-10.92%
2009 -C$68.01 Million95.77%
2008 -C$34.74 Million
2006 -C$55.65 Million-9.13%
2005 -C$61.25 Million34.74%
2004 -C$45.46 Million36.79%
2003 -C$33.23 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$0.75 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
C$7.00 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
C$87.65 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.35 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$49.31 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
C$17.93 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$10.43 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
C$1.16 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel